Xencor (NASDAQ:XNCR) Announces Earnings Results

Xencor (NASDAQ:XNCR) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.19, Zacks reports. The company had revenue of $52.79 million during the quarter, compared to analyst estimates of $17.14 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%.

Xencor Stock Up 4.2 %

NASDAQ:XNCR opened at $14.98 on Friday. Xencor has a 1 year low of $14.18 and a 1 year high of $27.24. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The stock has a 50-day moving average price of $19.79 and a two-hundred day moving average price of $20.68. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -4.68 and a beta of 0.70.

Insider Buying and Selling at Xencor

In other news, Director Alan Bruce Montgomery sold 1,421 shares of the stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $27.03, for a total value of $38,409.63. Following the transaction, the director now directly owns 9,140 shares of the company’s stock, valued at $247,054.20. This represents a 13.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 5.23% of the company’s stock.

Wall Street Analyst Weigh In

XNCR has been the subject of several recent research reports. BMO Capital Markets reiterated an “outperform” rating and set a $34.00 target price (up previously from $32.00) on shares of Xencor in a research note on Friday, November 8th. StockNews.com lowered Xencor from a “hold” rating to a “sell” rating in a research report on Wednesday. Wedbush reaffirmed an “outperform” rating and set a $38.00 price target on shares of Xencor in a research note on Thursday, November 7th. Wells Fargo & Company assumed coverage on shares of Xencor in a report on Thursday, December 12th. They set an “overweight” rating and a $37.00 target price for the company. Finally, Piper Sandler upgraded shares of Xencor from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $20.00 to $30.00 in a research report on Monday, December 2nd. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.88.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.